Testosterone therapy and prostate cancer risk is the question that stalls more men at the clinic door than any lab value ever will, and the honest answer is nuanced: treatment itself has not been shown to cause prostate cancer, but PSA needs to be tracked before, during, and after you start.
TL;DR
- Testosterone therapy prostate cancer risk is not elevated by treatment when PSA is checked every 90 days, per the 2023 TRAVERSE trial.
- Men with active, untreated prostate cancer should not start testosterone therapy without urologist clearance first.
- Injectable testosterone clears in 2-3 weeks if PSA rises; pellets take 3-5 months to fully clear. Buy injectables for reversibility.
- GoodLife Health's Biomarker Audit checks PSA every 90 days inside the $299/month membership, not as a separate charge.
Why this matters
For decades, urologists told men that testosterone "feeds" prostate cancer the way estrogen feeds some breast cancers, and hypogonadal men with any prostate history were turned away from treatment altogether. That model has been walked back. The protocol adjustments that matter for men over 50 starting testosterone therapy now hinge on PSA velocity and monitoring cadence, not a blanket prohibition.
The TRAVERSE trial, published in the New England Journal of Medicine in 2023, followed 5,246 hypogonadal men in a cardiovascular safety study and tracked prostate outcomes as a secondary endpoint. High-grade prostate cancer showed up in under 0.2% of both the testosterone group and the placebo group, with no statistically meaningful gap between them. That data reset the conversation for men in 2026 who had been told testosterone was off the table because of family history alone.
What the data does not say: that monitoring stops mattering. PSA still needs a baseline draw before the first dose, and it still needs rechecking on a schedule. The risk isn't testosterone causing cancer from scratch — it's an existing, undiagnosed cancer accelerating under treatment while nobody is watching the labs.
Who this is for
This guide is for men considering testosterone therapy who have a personal or family history of prostate cancer, an elevated or borderline PSA, benign prostatic hyperplasia, or simply enough caution to want a monitoring plan before they start. It is not a substitute for a urology consult if you have active, untreated prostate cancer — that conversation needs a specialist first, testosterone therapy second.
What to look for in testosterone therapy when prostate cancer risk is a concern
Baseline PSA and a documented digital rectal exam before the first dose
No clinic should write a testosterone prescription without a baseline PSA on file. If a platform skips straight from a symptom questionnaire to a vial, that's the first red flag, not the last. A baseline number is the only way to know later whether a rise is treatment-related or something that needed catching regardless.
A fixed recheck schedule, not a one-time lab
PSA needs rechecking at defined intervals after starting, then annually once stable. A single lab draw at intake and nothing after that is not monitoring, it's paperwork. Ask exactly how often labs repeat and whether the interval is written into the protocol or left to the patient to request.
Individualized risk stratification, not a blanket age cutoff
A 45-year-old with no family history and a normal prostate exam carries a different risk profile than a 62-year-old with a father who had prostate cancer at 58. Good protocols weigh age, race, family history, and baseline PSA together rather than applying one rule to every man walking in the door. Reading your testosterone lab results correctly means understanding what's actually being tracked alongside total and free testosterone.
Clear criteria for men with a treated, non-metastatic history
Men with successfully treated prostate cancer and an undetectable PSA are increasingly considered candidates for testosterone therapy under updated urology guidance, provided monitoring is tight. A clinic that still refuses categorically, without reviewing the individual case, is working off outdated assumptions rather than current evidence.
A modality that's easy to stop fast if PSA moves
Not all testosterone delivery methods clear from the body at the same speed. This matters more for prostate-cancer-conscious men than for anyone else starting therapy, because the ability to reverse course in weeks instead of months changes the risk calculus entirely.
Physician oversight that adjusts dose off labs, not a fixed protocol for everyone
Dosing that doesn't change regardless of what the labs show is a sign nobody is actually reading them. The clinician should be adjusting dose and frequency based on your specific PSA trend and hormone panel, not running a one-size template.
Top testosterone therapy options for prostate-cancer-conscious men
Injectable testosterone cypionate — the reversible pick. Weekly or biweekly injections carry a half-life of roughly 8 days, meaning levels drop measurably within 2 to 3 weeks of stopping. Paired with a 90-day PSA recheck, this is the easiest modality to pull back from fast if a number moves in the wrong direction. See testosterone therapy options for men in 2026 for the full comparison. Buy.
Testosterone pellets — the commitment pick. Pellets are inserted under the skin and release hormone steadily for 3 to 5 months, which is convenient for compliance but a problem if PSA spikes mid-cycle, since removal requires a minor surgical procedure rather than simply skipping a dose. Review testosterone pellet dosing before choosing this route if your baseline PSA is anywhere near borderline. Consider, only with a stable, low baseline PSA and no active surveillance status.
Topical testosterone gel — the daily-dial pick. Daily application means levels can drop within 24 to 48 hours of stopping, giving near-immediate reversibility. The tradeoff is transference risk to partners or children and less predictable absorption day to day. Consider, especially for men who want the fastest off-ramp available.
Compounded testosterone from unmonitored telehealth platforms — the one to flag. Testosterone therapy sold without a documented baseline PSA or a recheck schedule is common enough on discount platforms that it deserves its own line item. No lab before the first dose means no way to tell later whether a rise came from treatment or from something that was already there. Skip.
A physician-supervised protocol with a quarterly Biomarker Audit — the monitoring-first pick. GoodLife Health's Cardiometabolic Optimization Membership includes a comprehensive Biomarker Audit every 90 days, covering PSA alongside full hormone and thyroid panels, at a flat $299/month with zero markup on the testosterone itself. Buy, for men who want the monitoring built into the membership rather than billed as an extra.
What to avoid
- Stopping testosterone therapy cold on your own if PSA rises slightly. A single elevated number often warrants a recheck before any action, not a panic taper — talk to your clinician first.
- Assuming family history alone disqualifies you. Family history raises the bar for monitoring frequency, it doesn't automatically close the door on treatment in 2026.
- Trusting a symptom quiz instead of an actual lab draw. Any platform that prescribes testosterone off a questionnaire without a baseline PSA is skipping the one safeguard that matters most for this specific concern.
Verdict comparison
| Approach | PSA monitoring fit | Time to clear if PSA rises | Verdict |
|---|---|---|---|
| Injectable testosterone cypionate | Excellent with 90-day recheck | 2-3 weeks | Buy |
| Testosterone pellets | Good, but locked in mid-cycle | 3-5 months | Consider |
| Topical testosterone gel | Good | 24-48 hours | Consider |
| Compounded, unmonitored testosterone | Poor, often no baseline | Unknown | Skip |
FAQ
Does testosterone therapy cause prostate cancer?
No study to date has shown testosterone therapy causes prostate cancer from scratch. The 2023 TRAVERSE trial followed 5,246 men and found no significant difference in high-grade prostate cancer between testosterone and placebo groups, both under 0.2%.
Can I start testosterone therapy if I have a family history of prostate cancer?
Family history raises your monitoring priority, it does not automatically disqualify you. A baseline PSA and a tighter recheck schedule are the standard adjustment, not an outright refusal to treat.
How often should PSA be checked during testosterone therapy?
PSA is typically checked at baseline, then rechecked in the following months after starting, then annually once stable. A quarterly cadence, like a Biomarker Audit every 90 days, catches changes early rather than waiting a full year.
Can men with treated prostate cancer take testosterone therapy?
Men with successfully treated, non-metastatic prostate cancer and an undetectable PSA are increasingly considered candidates under updated urology guidance, with tighter monitoring than a man with no history. This decision needs a urologist involved, not a default yes or no.
What testosterone delivery method is safest for men worried about prostate cancer risk?
Injectable testosterone cypionate and topical gel clear from the body faster than pellets, making them easier to reverse if PSA rises. Pellets last 3 to 5 months and require a minor procedure to remove early, which is why they're a 'consider' rather than a first choice for this specific concern.
Is a rising PSA on testosterone therapy always a sign of cancer?
No. A modest PSA rise can reflect normal variation, an enlarged prostate, or a recent ejaculation before the blood draw, not necessarily cancer. It does warrant a recheck and, depending on the trend, a urology referral rather than an assumption either way.
Does GoodLife Health test PSA as part of testosterone therapy?
Yes. GoodLife Health's Cardiometabolic Optimization Membership includes a comprehensive Biomarker Audit every 90 days that covers PSA alongside full hormone and thyroid panels, for one flat $299 a month with no markup on the testosterone.
Should I stop testosterone therapy if my PSA goes up?
Talk to your clinician before stopping on your own. Depending on the magnitude of the rise and your history, the next step might be a recheck in a few weeks, a urology referral, or a dose adjustment, not an automatic discontinuation.
One last thing
The guideline that changed the most in the last few years isn't about who can start testosterone therapy, it's about who can restart it. Men who finish treatment for localized prostate cancer and hold an undetectable PSA for a defined stretch are now being evaluated as candidates in a growing number of urology practices, a reversal from the blanket lifetime ban that used to be standard. That's not a reason to self-diagnose your own candidacy. It's a reason to ask the question out loud instead of assuming the answer is no.
Related guides
- Testosterone therapy protocol adjustments for men over 50
- How to read your testosterone lab results
- Best testosterone therapy options for men in 2026
- Testosterone pellet dosing for men: what to expect
- Best GLP-1 medications for weight loss in 2026
References
- Testosterone Therapy in Men with Hypogonadism: An Endocrine Society Clinical Practice Guideline. 2018. doi.org/10.1210/jc.2018-00229